Please assess the completion status of the following clinical trial:

Trial Title: Pneumococcal Vaccination of Fiji Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy infant aged between 6 and 8 weeks~2. No significant maternal or perinatal history~3. Written and signed parental/caregiver consent~4. Lives within 30 minutes of the health clinic~5. Family anticipate living in the study area for the next 2 years~Exclusion Criteria:~1. Known allergy to any component of the vaccine~2. Allergic reaction or anaphylactoid reaction with previous vaccines~3. Known immunodeficiency disorder~4. HIV positive mother (many women are tested for HIV antenatally, however a test is not planned; therefore it would be based on clinic records or self report)~5. Known thrombocytopenia or coagulation disorder~6. On immunosuppressive medication~7. Received any blood product since birth~8. Severe congenital anomaly~9. Chronic or progressive disease~10. Seizure disorder~11. History of invasive Pneumococcal, meningococcal, or Haemophilus influenzae diseases~12. Moderate or severe acute infection (temporary exclusion); Minor illnesses such as an uncomplicated upper respiratory tract infection, localized skin infections, or mild diarrhea will not be an exclusion criterion

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 8 Weeks
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 18 months
- B (Type: EXPERIMENTAL): PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 12 months and 18 months
- C (Type: EXPERIMENTAL): PCV at 6 weeks and 14 weeks; PPS at 18 months
- D (Type: EXPERIMENTAL): PCV at 6 weeks and 14 weeks; PPS at 12 months and 18 months
- E (Type: EXPERIMENTAL): PCV at 14 weeks; PPS at 18 months
- F (Type: EXPERIMENTAL): PCV at 14 weeks; PPS at 12 months and 18 months
- G (Type: EXPERIMENTAL): No PCV; PPS at 12 months and 18 months
- H (Type: ACTIVE_COMPARATOR): No PCV; PPS at 18 months

Based on this trial design, predict the completion outcome and termination type (if applicable).